SUMOylation promotes PML degradation during encephalomyocarditis virus infection.
The promyelocytic leukemia (PML) protein is expressed in the diffuse nuclear fraction of the nucleoplasm and in matrix-associated structures, known as nuclear bodies (NBs). PML NB formation requires the covalent modification of PML to SUMO. The noncovalent interactions of SUMO with PML based on the identification of a SUMO-interacting motif within PML seem to be required for further recruitment within PML NBs of SUMOylated proteins. RNA viruses whose replication takes place in the cytoplasm and is inhibited by PML have developed various strategies to counteract the antiviral defense mediated by PML NBs. We show here that primary fibroblasts derived from PML knockout mice are more sensitive to infection with encephalomyocarditis virus (EMCV), suggesting that the absence of PML results in an increase in EMCV replication. Also, we found that EMCV induces a decrease in PML protein levels both in interferon-treated cells and in PMLIII-expressing cells. Reduction of PML was carried out by the EMCV 3C protease. Indeed, at early times postinfection, EMCV induced PML transfer from the nucleoplasm to the nuclear matrix and PML conjugation to SUMO-1, SUMO-2, and SUMO-3, leading to an increase in PML body size where the viral protease 3C and the proteasome component were found colocalizing with PML within the NBs. This process was followed by PML degradation occurring in a proteasome- and SUMO-dependent manner and did not involve the SUMO-interacting motif of PML. Together, these findings reveal a new mechanism evolved by EMCV to antagonize the PML pathway in the interferon-induced antiviral defense.
El McHichi
Bouchra
B
Université Paris Descartes, 75006 Paris, France.
Regad
Tarik
T
Maroui
Mohamed-Ali
MA
Rodriguez
Manuel S
MS
Aminev
Aleksey
A
Gerbaud
Sylvie
S
Escriou
Nicolas
N
Dianoux
Laurent
L
Chelbi-Alix
Mounira K
MK
D000818:Animals; D016466:CHO Cells; D018188:Cardiovirus Infections / Q000378:metabolism* / Q000821:virology; D002460:Cell Line; D002467:Cell Nucleus / Q000378:metabolism; D006224:Cricetinae; D003412:Cricetulus; D004686:Encephalomyocarditis virus / Q000502:physiology*; D006801:Humans; D045586:Intranuclear Inclusion Bodies / Q000378:metabolism; D051379:Mice; D018345:Mice, Knockout; D009687:Nuclear Proteins / Q000235:genetics / Q000378:metabolism*; D000071156:Promyelocytic Leukemia Protein; D011499:Protein Processing, Post-Translational; D021381:Protein Transport; D025841:Small Ubiquitin-Related Modifier Proteins / Q000378:metabolism*; D014157:Transcription Factors / Q000235:genetics / Q000378:metabolism*; D025521:Tumor Suppressor Proteins / Q000235:genetics / Q000378:metabolism*
D009687:Nuclear Proteins; C513293:Pml protein, mouse; D000071156:Promyelocytic Leukemia Protein; D025841:Small Ubiquitin-Related Modifier Proteins; D014157:Transcription Factors; D025521:Tumor Suppressor Proteins; C070576:PML protein, human
J Virol. 2001 Jul;75(13):6204-8
11390623
J Exp Med. 2001 Jun 18;193(12):1361-71
11413191
Virus Res. 2003 Sep;95(1-2):45-57
12921995
J Virol. 1992 Mar;66(3):1602-9
1310768
Virus Res. 2003 Sep;95(1-2):59-73
12921996
J Biol Chem. 1998 Oct 9;273(41):26675-82
9756909
Cell. 1991 Aug 23;66(4):675-84
1652369
Oncogene. 2001 Oct 29;20(49):7234-42
11704851
J Virol. 1998 May;72(5):3819-26
9557665
J Virol. 2006 Mar;80(6):2705-17
16501080
Biochimie. 2007 Jun-Jul;89(6-7):819-30
17343971
Cell. 2000 Apr 14;101(2):173-85
10786833
Nat Rev Immunol. 2008 Jul;8(7):559-68
18575461
Biochimie. 2007 Jun-Jul;89(6-7):713-8
17544197
J Virol. 1989 Mar;63(3):1054-8
2536819
Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3978-83
9108090
J Virol. 2009 Feb;83(4):1941-51
19073724
J Virol. 2009 May;83(10):5168-80
19279115
Cell. 1994 Jan 28;76(2):333-43
8293467
J Interferon Cytokine Res. 2006 May;26(5):271-80
16689655
J Gen Virol. 2004 Oct;85(Pt 10):2969-2979
15448360
J Virol. 1998 Feb;72(2):1043-51
9444998
J Virol. 2002 Apr;76(8):3810-8
11907221
Cell Microbiol. 2006 Mar;8(3):365-74
16469050
J Biol Chem. 2008 Sep 12;283(37):25660-25670
18635538
Proc Natl Acad Sci U S A. 1987 Jan;84(1):21-5
3467351
Oncogene. 2005 Jan 20;24(4):605-15
15580300
J Gen Virol. 2009 Mar;90(Pt 3):536-545
19218198
Oncogene. 2001 Oct 29;20(49):7274-86
11704856
Cell. 2006 Jul 28;126(2):269-83
16873060
Mol Cell. 2005 Apr 1;18(1):1-12
15808504
Oncogene. 2002 Nov 14;21(52):7957-70
12439746
Oncogene. 2001 Oct 29;20(49):7223-33
11704850
J Biol Chem. 2009 Jun 12;284(24):16595-16608
19380586
J Virol. 2007 Dec;81(23):13067-74
17728235
J Gen Virol. 1995 Aug;76 ( Pt 8):1999-2007
7636480
J Virol. 1980 Aug;35(2):414-9
6255181
Nat Genet. 1998 Nov;20(3):266-72
9806545
J Biol Chem. 2001 Sep 21;276(38):35368-74
11451954
Virology. 2009 Sep 1;391(2):171-6
19628239
Nat Rev Mol Cell Biol. 2009 Aug;10(8):564-8
19474794
Virology. 2007 Apr 10;360(2):350-63
17150238
Virus Genes. 1996;13(2):99-110
8972564
J Virol. 1980 Sep;35(3):732-40
6252335
Leukemia. 1995 Dec;9(12):2027-33
8609713
Cell Microbiol. 2010 Mar;12(3):310-7
19863558
Mol Cell. 2006 Nov 3;24(3):331-9
17081985
J Virol. 1974 Sep;14(3):598-610
4368674
EMBO J. 2001 Jul 2;20(13):3495-505
11432836
Nat Rev Drug Discov. 2007 Dec;6(12):975-90
18049472
EMBO J. 1994 Mar 1;13(5):1073-83
8131741
Cell Microbiol. 2007 Dec;9(12):2921-30
17991048
J Virol. 2006 Sep;80(17):8582-92
16912307
Oncogene. 1995 Dec 21;11(12):2565-73
8545113